J3357 HCPCS code: Ustekinumab, for subcutaneous injection, 1 mg
J3357 is the HCPCS Level II code for ustekinumab, for subcutaneous injection, 1 mg. In 2024 Medicare paid an average of $84.59 per service for J3357 across 19,937 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 90 per day on outpatient hospital claims. Medicare volume fell 91% from 2022 to 2024 (232,387 to 19,937 services). In 2024, about 174 clinicians billed Medicare for J3357 for 146 beneficiaries; Georgia, Ohio, Alabama accounted for 72% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2011-01-01 |
| Last action effective | 2017-01-01 |
Who bills J3357 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 174 |
| Medicare beneficiaries | 146 |
| States with claims | 5 |
| Share of services in top 3 states (Georgia, Ohio, Alabama) | 72% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3357, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 232,387 | 1,411 | $156.89 | $125.30 |
| 2023 | 16,760 | 159 | $113.17 | $90.13 |
| 2024 | 19,937 | 146 | $105.93 | $84.59 |
States with the most J3357 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Georgia | 4,324 | $92.12 |
| Ohio | 3,337 | $72.79 |
| Alabama | 3,285 | $112.62 |
| North Carolina | 2,869 | $107.79 |
| Kentucky | 1,421 | $0.80 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 90 | Clinical: Data |
| practitioner claims | 90 | Clinical: Data |
What changed for J3357
- 2011-01-01: J3357 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3357?
J3357 is the HCPCS Level II code for ustekinumab, for subcutaneous injection, 1 mg. Short descriptor: "Ustekinumab sub cu inj, 1 mg".
How much does Medicare pay for J3357?
In 2024, the average Medicare payment was $84.59 per service (average allowed $105.93).
Does Medicare cover J3357?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J3357 can be billed per day?
90 on outpatient hospital claims; 90 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3300 — Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
- J3301 — Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3357
- Watch J3357 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3357
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.